Emperra said today that it closed a Series B round worth $3.1 million for its Esysta “smart” diabetes management system.
Potsdam, Germany-based Emperra said the VC arm of the Bosch Group, Robert Bosch Venture Capital, joined existing backers Peppermint VenturePartners and Investitionsbank des Landes Brandenburg. CEO Christian Krey and CTO Dr. Janko Schildt also got in on the round, Emperra said.
Esysta, which uses a Bluetooth-enable insulin pen and a wireless blood glucose meter to monitor diabetes patients, won CE Mark approval in the European Union and reimbursement coverage from German health insurers, Emperra said. Patients and healthcare providers can view data from the system via a web portal, smart TV and mobile device apps, the company said.
The Series B funding is earmarked for product development and sales growth in the U.S. and Europe, Emperra said.
“Involving high-quality investors such as Bosch demonstrates the potential in our unique approach to diabetes care,” Krey said in prepared remarks. “In particular, having Bosch as a strategic investor means we have access to its global expertise in software automation, connected communities, and sensor technologies.”
“As 1 of the lead investors of the Series A round, we continued to support Emperra by participating in the B round. We are pleased to add RBVC to our syndicate, and hope it will accelerate Emperra’s expansion into international markets,” added acting chairman Klaus Stoeckemann of Peppermint VenturePartner.